Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 80

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 80
---
21,383 | ) |     |          | (360,012 | ) |     |      |   (43,534 | ) |
| Net loss before income taxes                                                              |     |                       |    (19,354 | ) |     |      |  (122,454 | ) |     |          | (534,739 | ) |     |      |  (267,387 | ) |
| Income tax provision                                                                      |     |                       |          - |   |     |      |         - |   |     |          |        - |   |     |      |         - |   |
| Net loss                                                                                  |     |                       |    (19,354 | ) |     |      |  (122,454 | ) |     |          | (534,739 | ) |     |      |  (267,387 | ) |
| Net income (loss) attributable to common shareholders                                     |     |                       |    (19,354 | ) |     |      |  (122,454 | ) |     |          | (534,739 | ) |     |      |  (267,387 | ) |
| Per common share basic and diluted:                                                       |     |                       |            |   |     |      |           |   |     |          |          |   |     |      |           |   |
| Net loss per common share attributable to Regen Biopharma shareholders, basic and diluted |     |                       |      (0.00 | ) |     |      |     (0.03 | ) |     |          |    (0.03 | ) |     |      |     (0.07 | ) |
| Number of weighted average shares - basic and diluted                                     |     |                       | 21,554,704 |   |     |      | 4,110,265 |   |     |          | 18730773 |   |     |      | 3,596,027 |   |

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(unaudited)

|                                       |     | Six Months Ended 
 March 31, 2025   |          |   |